text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

请选择数量

CAS RN: 192927-63-2 | 产品编码: M2479

Moxifloxacin Hydrochloride Monohydrate


纯度/分析方法: >98.0%(T)(HPLC)
别名:
  • 莫西沙星盐酸盐 一水合物
  • 1-环丙基-6-氟-1,4-二氢-8-甲氧基-7-[(4aS,7aS)-十氢-1H-吡咯并[3,4-b]吡啶-6-基]-4-氧代-3-喹啉甲酸盐酸盐 一水合物
  • 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic Acid Hydrochloride Monohydrate
产品文档:
100MG
S$169.50
3   0   下单后约2周内可以发货
1G
S$850.50
6   0   下单后约2周内可以发货

* 订购TCI产品,请联系我们的经销商或 联系我们。
* TCI会时常优化储存条件,敬请留意。


产品编码 M2479
纯度/分析方法 >98.0%(T)(HPLC)
分子式/分子量 C__2__1H__2__4FN__3O__4·HCl·H__2O = 455.92 
外观与形状(20°C) 固体
储存温度 室温 (15°C以下阴凉干燥处)
包装和容器 100MG-Glass Bottle with Plastic Insert (查看图片),  1G-Glass Bottle with Plastic Insert (查看图片)
CAS RN 192927-63-2
相关CAS RN 186826-86-8&151096-09-2
Reaxys-RN 8377447
PubChem物质ID 354334556
Merck Index (14) 6291
MDL编号

MFCD00949117

技术规格
Appearance White to Orange to Green powder to crystaline
Purity(HPLC) min. 98.0 area%
Purity(Neutralization titration) min. 98.0 %
Specific rotation [a]20/D -124 to -137 deg(C=0.5, water)
Water 3.0 to 5.0 %
物性(参考值)
熔点 240 °C(dec.)
最大吸收波长 338 nm (H__2O)
GHS
象形图 Pictogram
信号词 Warning
危险性说明 H341 : Suspected of causing genetic defects.
防范说明 P501 : Dispose of contents/ container to an approved waste disposal plant.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P405 : Store locked up.
相关法规
RTECS# VB1983750
运输信息
HS编码* 2933.49-000
*此H.S.编码用于日本出口报关,不适用于您所在国家或地区的进口申报
应用
Moxifloxacin Hydrochloride: A Fluoroquinolone Antibacterial with a Methoxy Group in the C-8 Position

Moxifloxacin hydrochloride (BAY 12-8039) is a synthetic fluoroquinolone antibacterial agent with in vitro activity against a wide range of Gram-positive and Gram-negative bacteria. The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) in Gram-negative bacteria and topoisomerase IV in Gram-positive bacteria required for bacterial DNA replication, transcription, repair, and recombination. It is reported that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. Therefore, moxifloxacin has improved activity against Gram-positive species (including staphylococci, streptococci, enterococci) compared with ciprofloxacin [ C2510, C2227 (HCl salt)]. Recently, antituberculosis activity of moxifloxacin has been reported. (The product is for research purpose only.)

References


参考文献


技术文章
产品文档 (部分产品的分析图谱无法提供,敬请谅解。)
化学品安全说明书(SDS)
请选择语言。

如需更多帮助,请联系我 们。

技术规格
CoA及其他文档
请输入批号 批号输入有误。请输入中横线前的4-5个字母数字字符。

您查询的批号对应的产品已停产,相关文档将不再提供。请尝试该产品的其他批号。

示例 CoA
可下载CoA示例。注:该示例不一定是最新批次的CoA。

目前没有该产品的 CoA 示例。

分析图谱
请输入批号 批号输入有误。请输入中横线前的4-5个字母数字字符。

很抱歉,您搜索的分析图谱无法提供。

您查询的批号对应的产品已停产,相关文档将不再提供。请尝试该产品的其他批号。

其他文件

会话状态
当前会话将在10分钟后超时,并返回主页。请点击按钮继续浏览。分钟后超时,并返回主页。请点击按钮继续浏览。

您的会话已超时,将返回至主页。